Andrew Ball, Chief Executive Officer, brings over 20 years of global leadership experience and value creation in the life sciences industry, with a successful track record in technological and commercial development of assay platforms and services, spanning startups to large multinationals. Prior to joining SeromYx in 2025, he served as Vice President, Assay Development Platforms at Abcam, a Danaher company, where he led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services. He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for neurodegenerative disease and immuno-oncology; as VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in a variety of innovation and strategic leadership roles at MilliporeSigma. He studied at Ulster University and held post-doctoral positions at Louisiana State University and the Sanford-Burnham Medical Institute.